CMS, International Regulators’ Use Of Reference Pricing Causes Concern
This article was originally published in The Gray Sheet
Executive Summary
The initial launch price of a device into a foreign market may become fixed worldwide as CMS and foreign regulators increasingly rely on reference pricing, J&J/Cordis VP-Medical Affairs & Health Economics Brian Firth, MD/PhD, cautions